Welcome to our dedicated page for Roivant Sciences news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roivant Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roivant Sciences's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BOSTON, March 28, 2023 — Covant Therapeutics has announced an exclusive research collaboration with Boehringer Ingelheim focusing on its ADAR1 program to develop a small molecule immunotherapy for cancer patients. Covant's platform accelerates drug discovery for challenging targets like ADAR1. The partnership aims to create an ADAR1 inhibitor to enhance the efficacy of existing immunotherapies. Covant will receive an upfront payment of $10 million and has the potential to earn up to $471 million in milestones along with royalties on global sales. This collaboration highlights ADAR1’s potential to improve cancer treatments and reflects confidence in Covant's innovative approach.
Dermavant Sciences, a Roivant Sciences company, announced positive results from the ADORING 2 Phase 3 trial evaluating VTAMA cream for atopic dermatitis. The study demonstrated that 46.4% of subjects using VTAMA achieved the primary endpoint of clear or almost clear skin, significantly outperforming the vehicle group (18.0%, P<0.0001). Key secondary endpoints were also met, including a 59.1% improvement in EASI scores. The trial showed a rollover rate of 92.4% into a long-term safety study, indicating strong patient retention. VTAMA is already approved for plaque psoriasis, providing a potential advantage in treatment regimens for both children and adults.